Your browser doesn't support javascript.
loading
Reward drinking and naltrexone treatment response among young adult heavy drinkers.
Roos, Corey R; Bold, Krysten W; Witkiewitz, Katie; Leeman, Robert F; DeMartini, Kelly S; Fucito, Lisa M; Corbin, William R; Mann, Karl; Kranzler, Henry R; O'Malley, Stephanie S.
Afiliação
  • Roos CR; Department of Psychiatry, Yale School of Medicine, New Haven, CT, USA.
  • Bold KW; Department of Psychiatry, Yale School of Medicine, New Haven, CT, USA.
  • Witkiewitz K; Department of Psychology, University of New Mexico, Albuquerque, NM, USA.
  • Leeman RF; Department of Psychiatry, Yale School of Medicine, New Haven, CT, USA.
  • DeMartini KS; Department of Health Education and Behavior, University of Florida, Gainesville, FL, USA.
  • Fucito LM; Department of Psychiatry, Yale School of Medicine, New Haven, CT, USA.
  • Corbin WR; Department of Psychiatry, Yale School of Medicine, New Haven, CT, USA.
  • Mann K; Department of Psychology, Arizona State University, Tempe, AZ, USA.
  • Kranzler HR; Central Institute of Mental Health, Medical Faculty Mannheim, University of Heidelberg, Mannheim, Germany.
  • O'Malley SS; Perelman School of Medicine, University of Pennsylvania and Crescenz VAMC, Philadelphia, PA, USA.
Addiction ; 116(9): 2360-2371, 2021 09.
Article em En | MEDLINE | ID: mdl-33620746
AIMS: Theory-driven, exploratory study to: (i) identify a reward drinking phenotype in young adults; (ii) evaluate this phenotype as a predictor of naltrexone response; and (iii) examine mechanisms of naltrexone in reward drinkers. DESIGN: Secondary analysis of a randomized controlled trial. SETTING: USA. PARTICIPANTS: A total of 128 young adult (ages 18-25) heavy drinkers. INTERVENTIONS: Naltrexone versus placebo. MEASUREMENTS: Daily surveys assessed affect, urge, drinking, and context. The Drinking Motives Questionnaire was used to identify phenotypes based on reward (enhancement motives) and relief (coping motives) drinking. FINDINGS: We identified three profiles: "Low reward/Low relief" (14.1%; low enhancement/low coping motives); "Reward drinkers" (62.2%; high enhancement/low coping motives); and "High reward/High relief" (22.7%; high enhancement/high coping motives). Among reward drinkers (versus low profile), naltrexone significantly reduced percent days drinking to intoxication (blood alcohol concentration [BAC] ≥0.08) (PDI) (d = 0.56; 95% CI [0.17, 0.96]) and percent high intensity drinking days (PHID) (8/10 drinks for women/men) (d = 0.32; 95% CI [0.01, 0.68]). Among the high reward/high relief profile drinkers (versus low profile), naltrexone reduced PHID (d = 0.69; 95% CI [0.02, 1.50]). Using profile-informed cutoffs and observed scores (for clinical applicability): (i) among cutoff-derived reward drinkers, we found a medium-to-large (d = 0.66; 95% CI [0.24, 1.16]) and small effect (d = 0.28; 95% CI [0.04, 0.72]) of naltrexone in reducing PDI and PHID, respectively; and (ii) among the cutoff-derived high reward/high relief subgroup, we found a medium-to-large effect (d = 0.63; 95% CI [0.05, 1.1]) of naltrexone in reducing PHID. Among reward drinkers (not other profiles), naltrexone reduced drinking on days a drinking event occurred by weakening the within-day association between positive affect and urges (P < 0.05). CONCLUSIONS: Naltrexone has pronounced effects in reducing risky drinking among young adult reward drinkers (high reward/low relief) by reducing urges on days when individuals have higher positive affect and are exposed to a drinking event. Naltrexone also appears to reduce risky drinking among young adult high reward/high relief drinkers, but not via the same mechanism.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Alcoolismo / Naltrexona Idioma: En Ano de publicação: 2021 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Alcoolismo / Naltrexona Idioma: En Ano de publicação: 2021 Tipo de documento: Article